Zai Lab Limited [NASDAQ: ZLAB] jumped around 29.24 points on Tuesday, while shares priced at $161.29 at the close of the session, up 22.14%. The company report on April 13, 2021 that Zai Lab Partner Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer.
Pre-specified interim analysis concluded with favorable recommendation to continue the LUNAR trial.
DMC stated accrual to 534 patients is likely unnecessary and possibly unethical for patients randomized to control arm and recommended a shortened trial.
Zai Lab Limited stock is now 19.17% up from its year-to-date (YTD) trading value. ZLAB Stock saw the intraday high of $161.64 and lowest of $145.92 per share. The company’s 52-week high price is 193.54, which means current price is +31.50% above from all time high which was touched on 01/20/21.
Compared to the average trading volume of 434.49K shares, ZLAB reached a trading volume of 1560714 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Zai Lab Limited [ZLAB]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ZLAB shares is $174.29 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ZLAB stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Zai Lab Limited shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 28, 2020. While these analysts kept the previous recommendation, Guggenheim raised their target price to Buy. The new note on the price target was released on April 15, 2020, representing the official price target for Zai Lab Limited stock.
The Average True Range (ATR) for Zai Lab Limited is set at 9.10, with the Price to Sales ratio for ZLAB stock in the period of the last 12 months amounting to 304.21. The Price to Book ratio for the last quarter was 11.24, with the Price to Cash per share for the same quarter was set at 12.84.
How has ZLAB stock performed recently?
Zai Lab Limited [ZLAB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 26.31. With this latest performance, ZLAB shares gained by 12.25% in over the last four-week period, additionally plugging by 73.43% over the last 6 months – not to mention a rise of 177.80% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZLAB stock in for the last two-week period is set at 65.83, with the RSI for the last a single of trading hit 75.27, and the three-weeks RSI is set at 60.28 for Zai Lab Limited [ZLAB]. The present Moving Average for the last 50 days of trading for this stock 149.80, while it was recorded at 138.83 for the last single week of trading, and 112.10 for the last 200 days.
Zai Lab Limited [ZLAB]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Zai Lab Limited [ZLAB] shares currently have an operating margin of -616.45 and a Gross Margin at +65.82. Zai Lab Limited’s Net Margin is presently recorded at -549.26.
Return on Total Capital for ZLAB is now -40.09, given the latest momentum, and Return on Invested Capital for the company is -36.11. Return on Equity for this stock declined to -36.71, with Return on Assets sitting at -32.51. When it comes to the capital structure of this company, Zai Lab Limited [ZLAB] has a Total Debt to Total Equity ratio set at 1.59. Additionally, ZLAB Total Debt to Total Capital is recorded at 1.57, with Total Debt to Total Assets ending up at 1.43. Long-Term Debt to Equity for the company is recorded at 1.15, with the Long-Term Debt to Total Capital now at 1.13.
Reflecting on the efficiency of the workforce at the company, Zai Lab Limited [ZLAB] managed to generate an average of -$1,746,755 per employee. Receivables Turnover for the company is 10.91 with a Total Asset Turnover recorded at a value of 0.06.Zai Lab Limited’s liquidity data is similarly interesting compelling, with a Quick Ratio of 12.30 and a Current Ratio set at 12.40.
Insider trade positions for Zai Lab Limited [ZLAB]
There are presently around $7,075 million, or 66.20% of ZLAB stock, in the hands of institutional investors. The top three institutional holders of ZLAB stocks are: CAPITAL WORLD INVESTORS with ownership of 8,551,442, which is approximately 23.102% of the company’s market cap and around 1.18% of the total institutional ownership; FMR LLC, holding 4,926,748 shares of the stock with an approximate value of $650.58 million in ZLAB stocks shares; and BAILLIE GIFFORD & CO, currently with $508.41 million in ZLAB stock with ownership of nearly 6.876% of the company’s market capitalization.
Positions in Zai Lab Limited stocks held by institutional investors increased at the end of June and at the time of the June reporting period, where 123 institutional holders increased their position in Zai Lab Limited [NASDAQ:ZLAB] by around 8,078,558 shares. Additionally, 63 investors decreased positions by around 4,191,869 shares, while 21 investors held positions by with 41,310,909 shares. The mentioned changes placed institutional holdings at 53,581,336 shares, according to the latest SEC report filing. ZLAB stock had 35 new institutional investments in for a total of 917,356 shares, while 20 institutional investors sold positions of 330,450 shares during the same period.